UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
A retrospective study to determine the impact of psychedelic therapy for dimensional measures of wellness: A qualitative analysis of response data
The use of various psychedelic medicines appears to be associated with a broad range of qualitative experiences that could help clarify ... how they impact wellness in the future.
Could MDMA’s UK approval be fast tracked by forthcoming Reciprocal Drug Approval Procedure with FDA?
Might MAPS PBC’s MDMA-assisted therapy for PTSD be among the first products considered under this new UK reciprocal drug approval pathway?
Beckley Psytech receives FDA approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT
This Phase IIb randomised, dose-finding study will evaluate the effects of a single dose of BPL-003 in patients with moderate to severe TRD who are not taking concomitant antidepressants.
The Psychedelic Educators Network
Christine Ziemer has established an international network of professors and instructors who are teaching (or, plan to teach) psychedelics-related courses.
Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis
The synthesis of findings identified three themes that were common across the studies despite the health condition: acceptance, connection and transformation.
The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists
we suggest there is scope to develop up-to-date education about psychedelics for psychiatrists.
Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample
Lifetime MDMA/ecstasy use was associated with lowered odds of three of our four social impairment outcomes.
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
This study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics.
Therapeutic effect of psilocybin in addiction: A systematic review
Larger RCTs in patients with SUDs need to evaluate whether psilocybin-assisted therapy is effective in patients with SUD.
Experts' mixed responses to the surprise announcement of psilocybin & MDMA becoming (limitedly) licensed in Australia
The Australian Therapeutic Goods Administration has announced that psilocybin for treatment-resistant depression and MDMA for PTSD will be legally prescribable.
Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being
The findings are consistent with the hypothesis that some of the benefits of psychedelic-induced mystical experiences on subjective well-being may emerge due to reductions in death anxiety.
Australia becomes first country to recognise psychedelics as medicines
In a surprising move, Australia’s Therapeutic Goods Administration (TGA) has announced that it will permit the prescribing of MDMA and Psilocybin from the 1st of July.
“After the Ecstasy, the Laundry” – Shayla Love’s take on psychedelics in 2022 – Psychedelic Alpha
Themes that shaped the psychedelics space in 2022, plus her hopes and predictions for the coming year.
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients
Findings suggest that psilocybin-assisted therapy facilitates psycho-social-spiritual growth as measured by the NIH-HEALS and its three factors.
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience.
Small Pharma reports positive top-line results from phase IIa trial of SPL026 in major depressive disorder
intravenous N,N-Dimethyltryptamine (“DMT”), with supportive therapy for the treatment of MDD met the primary endpoint in its Phase IIa clinical trial.